As of early July 2026, the Smith and Nephew share price on the London Stock Exchange (ticker: SN.) is trading around 1,090–1,150 pence (GBX) per share, roughly £10.90–£11.50. Its NYSE-listed ADR (ticker: SNN) trades separately at around $30. Prices change throughout each trading day.
What Is Smith & Nephew?
Before diving into the Smith and Nephew share price, it helps to know the company itself. Smith & Nephew plc is a British medical technology company founded in 1856 and headquartered in Watford, UK.
The company makes products across three main segments:
- Orthopaedics — knee and hip implants, trauma products
- Sports Medicine & ENT — joint repair tools and arthroscopic technology
- Advanced Wound Management — wound care devices and regenerative medicine
It employs roughly 17,000 people worldwide. Therefore, its share price is often watched closely by investors interested in the healthcare and medtech sectors.
Definition: The Smith and Nephew share price is the current market value of one ordinary share of Smith & Nephew plc, as traded on the London Stock Exchange under ticker SN., or its American Depositary Receipt (ADR) traded on the NYSE under ticker SNN.
Smith and Nephew Share Price Today
Here’s a snapshot of recent trading data:
- LSE (SN.): Around 1,090–1,150 GBX (pence) per share, with a recent day range near 1,079–1,150 GBX
- 52-week range: Roughly 1,062 GBX to 1,441 GBX
- NYSE ADR (SNN): Around $30, with a recent 12-month range that has moved between roughly $30 and higher levels earlier in the year
- Market capitalisation: Approximately £9–10 billion
However, these figures are a snapshot only. As a result, you should always check a live broker or exchange feed for the exact current Smith and Nephew share price before acting on it.
LSE vs NYSE: Where Is It Listed?
Smith & Nephew has a dual listing structure, which sometimes confuses new investors:
- London Stock Exchange (ticker: SN.) — the primary listing, priced in pence (GBX), part of the FTSE 100 index.
- New York Stock Exchange (ticker: SNN) — an American Depositary Receipt (ADR), priced in US dollars, representing shares of the same underlying company.
Because these trade on different exchanges in different currencies, the numeric Smith and Nephew share price will look very different depending on which one you’re checking. Furthermore, currency exchange rates and trading hours also cause small timing differences between the two.
Share Price History: The Past Year
Looking at the past 12 months adds useful context to the current Smith and Nephew share price:
- The stock’s 52-week high on the LSE has been reported around 1,441.50 GBX
- The 52-week low has been reported around 1,062.50 GBX
- Year-over-year, LSE shares have shown gains in the low-to-double-digit percentage range depending on the exact measurement window
- The stock has, at times, underperformed the broader FTSE All-Share Index over shorter periods, including a reported six-month lag of roughly -14.7%
Therefore, while the shares have gained ground over the past year, performance relative to the wider market has been mixed at different points.
Key Financial Metrics
Beyond the raw Smith and Nephew share price, these metrics help investors judge the stock:
| Metric | Approximate Value |
| P/E ratio (trailing) | ~13 |
| Dividend yield | ~1.5%–2.5% (varies by source/date) |
| EPS (TTM) | ~$0.72 |
| Market cap | ~£9–10 billion |
| Next earnings report | August 4, 2026 |
As a result, Smith & Nephew currently trades at a relatively moderate P/E ratio compared to many healthcare peers, though this changes as the share price and earnings move.
What Moves the Smith and Nephew Share Price?
Several factors typically influence how the Smith and Nephew share price moves:
- Quarterly and annual earnings reports, including revenue from orthopaedics and wound care segments
- Analyst rating changes, such as upgrades or downgrades from firms covering the stock
- New product launches, including robotics platforms like its CORI XT handheld system for knee procedures
- Broader FTSE 100 and healthcare-sector trends
- Currency fluctuations, since the company reports in multiple currencies and its ADR trades in US dollars
Recent analyst commentary has included at least one rating downgrade from “buy” to “hold” alongside a reduced price target, illustrating how quickly sentiment can shift.
Analyst Ratings and Price Targets
Analyst sentiment is a common data point investors check alongside the Smith and Nephew share price itself:
- Overall consensus rating has recently been reported as “Buy” on some platforms, with multiple analysts recommending purchase and none recommending sale
- Average 12-month price targets reported around 1,390–1,400 GBX, with estimates ranging roughly from 1,207 GBX to 1,636 GBX
- At least one major analyst firm has moved its rating to “Hold” with a lowered target
Because analyst opinions vary and change often, it’s worth comparing multiple sources rather than relying on a single rating.
LSE vs NYSE Snapshot Comparison
| Feature | LSE (SN.) | NYSE ADR (SNN) |
| Currency | GBX (pence) | USD |
| Recent price range | ~1,090–1,150 GBX | ~$30 |
| Index membership | FTSE 100 | Not a US index component |
| Trading hours | UK market hours | US market hours |
| Reflects | Direct ordinary shares | Depositary receipt of same shares |
FAQs About Smith and Nephew Share Price
What is the Smith and Nephew share price today?
As of early July 2026, LSE shares (SN.) trade around 1,090–1,150 GBX, while the NYSE ADR (SNN) trades around $30. Check a live feed for the exact current price.
Is Smith and Nephew listed on the NYSE or LSE?
Both. The primary listing is on the London Stock Exchange (SN.), with an American Depositary Receipt (SNN) also trading on the NYSE.
What is the Smith and Nephew dividend yield?
Recent reports place the dividend yield in a range of roughly 1.5% to 2.5%, though this shifts as the share price and payout change.
When does Smith and Nephew report earnings next?
Its next scheduled earnings report is August 4, 2026, based on recent data.
What is the analyst consensus on Smith and Nephew stock?
Ratings have recently ranged from “Buy” to “Hold” depending on the analyst firm, with average 12-month price targets generally above the current trading price.
Conclusion
The Smith and Nephew share price reflects a company balancing steady medtech demand with shifting analyst sentiment and currency effects across its dual LSE and NYSE listings. Therefore, anyone tracking this stock should look beyond the headline number — dividend yield, P/E ratio, and analyst targets all add useful context.
For the most accurate, real-time Smith and Nephew share price, check your brokerage platform or a live exchange feed, since figures here are a point-in-time snapshot rather than live data. This article is informational only and not a recommendation to buy or sell.
You may also read: Fame Post
